Epstein-Barr virus lytic gene BNRF1 promotes B-cell lymphomagenesis via IFI27 upregulation

PLoS Pathog. 2024 Feb 1;20(2):e1011954. doi: 10.1371/journal.ppat.1011954. eCollection 2024 Feb.

Abstract

Epstein-Barr virus (EBV) is a ubiquitous human lymphotropic herpesvirus that is causally associated with several malignancies. In addition to latent factors, lytic replication contributes to cancer development. In this study, we examined whether the lytic gene BNRF1, which is conserved among gamma-herpesviruses, has an important role in lymphomagenesis. We found that lymphoblastoid cell lines (LCLs) established by BNRF1-knockout EBV exhibited remarkably lower pathogenicity in a mice xenograft model than LCLs produced by wild-type EBV (LCLs-WT). RNA-seq analyses revealed that BNRF1 elicited the expression of interferon-inducible protein 27 (IFI27), which promotes cell proliferation. IFI27 knockdown in LCLs-WT resulted in excessive production of reactive oxygen species, leading to cell death and significantly decreased their pathogenicity in vivo. We also confirmed that IFI27 was upregulated during primary infection in B-cells. Our findings revealed that BNRF1 promoted robust proliferation of the B-cells that were transformed by EBV latent infection via IFI27 upregulation both in vitro and in vivo.

MeSH terms

  • Animals
  • Epstein-Barr Virus Infections*
  • Herpesviridae* / metabolism
  • Herpesvirus 4, Human
  • Humans
  • Interferons / metabolism
  • Membrane Proteins / metabolism
  • Mice
  • Up-Regulation
  • Virus Latency

Substances

  • Interferons
  • IFI27 protein, human
  • Membrane Proteins

Grants and funding

This work was supported in part by grants from the Japan Society for the Promotion of Science (JSPS) KAKENHI (Grant Numbers JP23K06559 to Y.S., JP23H02723 to H.Kimura., and JP22H02878 to Y.O.); the Japan Science and Technology Agency (JST) PRESTO (Grant Number JPMJPR19H5 to Y.S.), and CREST (Grant Number JPMJCR19H4 to Y.S. and S.T.); the Japan Agency for Medical Research and Development (AMED) (JP21wm0325042 to Y.S.); the Chemo-Sero-Therapeutic Research Institute to H.K.; the Aichi Health Promotion Foundation to K.S. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.